The estimated Net Worth of Armando Anido is at least $2.65 Milión dollars as of 12 September 2023. Mr. Anido owns over 17,830 units of Zynerba Pharmaceuticals Inc stock worth over $1,217,739 and over the last 9 years he sold ZYNE stock worth over $58,075. In addition, he makes $1,369,570 as Chairman of the Board a Chief Executive Officer at Zynerba Pharmaceuticals Inc.
Sign up
Mr. Anido ZYNE stock SEC Form 4 insiders trading
Armando has made over 6 trades of the Zynerba Pharmaceuticals Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he sold 17,830 units of ZYNE stock worth $23,714 on 12 September 2023.
The largest trade he's ever made was selling 35,453 units of Zynerba Pharmaceuticals Inc stock on 23 January 2023 worth over $21,272. On average, Armando trades about 3,340 units every 86 days since 2015. As of 12 September 2023 he still owns at least 936,722 units of Zynerba Pharmaceuticals Inc stock.
You can see the complete history of Mr. Anido stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Armando Anido biography
Armando Anido serves as Chairman of the Board, Chief Executive Officer of the Company. Mr. Anido has served as chairman of our Board and as our chief executive officer since October 2014. Prior to joining our company, Mr. Anido served as our business consultant from May 2014 to October 2014. Mr. Anido has more than 35 years of executive, operational and commercial leadership experience in the pharmaceutical industry. Mr. Anido served as chief executive officer and as a director of NuPathe, Inc., or NuPathe, a publicly-traded specialty pharmaceutical company, from July 2012 through March 2014, during which time he led the company through U.S. Food and Drug Administration, or FDA, approval of its lead product Zecuity®, a transdermal patch for migraines. Prior to joining NuPathe, Mr. Anido served as chief executive officer and president and as a director of Auxilium Pharmaceuticals, Inc., or Auxilium, a specialty pharmaceutical company, from July 2006 through December 2011, where he led the company in its commercialization of its lead product, Testim®, a testosterone gel. Additionally, Mr. Anido led the company through the FDA approval and commercialization of Xiaflex®, an injectable collagenase for Dupuytren's Contracture. Mr. Anido currently serves as a director of Auris Medical, a pharmaceutical company, and has held such position since April 2016, and as a director of Scynexis, Inc. a pharmaceutical company, and has held such position since January 2019. He formerly served as a director of Aviragen Therapeutics, a pharmaceutical company, from October 2015 to March 2018, Respira Therapeutics, Inc., a pharmaceutical company, from May 2012 through September 2014, and Adolor Corporation, a pharmaceutical company, from September 2003 through December 2011. Mr. Anido holds a B.S. in Pharmacy and an MBA, both from West Virginia University. With more than 35 years of experience in the pharmaceutical industry, Mr. Anido brings valuable executive, operational and commercial expertise to our Board.
What is the salary of Armando Anido?
As the Chairman of the Board a Chief Executive Officer of Zynerba Pharmaceuticals Inc, the total compensation of Armando Anido at Zynerba Pharmaceuticals Inc is $1,369,570. There are no executives at Zynerba Pharmaceuticals Inc getting paid more.
How old is Armando Anido?
Armando Anido is 62, he's been the Chairman of the Board a Chief Executive Officer of Zynerba Pharmaceuticals Inc since 2014. There are 7 older and 6 younger executives at Zynerba Pharmaceuticals Inc. The oldest executive at Zynerba Pharmaceuticals Inc is Daniel Kisner, 72, who is the Independent Director.
What's Armando Anido's mailing address?
Armando's mailing address filed with the SEC is 1 EVERTRUST PLAZA, 13TH FLOOR, JERSEY CITY, NJ, 07302-6548.
Insiders trading at Zynerba Pharmaceuticals Inc
Over the last 9 years, insiders at Zynerba Pharmaceuticals Inc have traded over $154,101 worth of Zynerba Pharmaceuticals Inc stock and bought 224,703 units worth $2,383,877 . The most active insiders traders include John P. Butler, William J Federici a Michael Rapp. On average, Zynerba Pharmaceuticals Inc executives and independent directors trade stock every 69 days with the average trade being worth of $12,515. The most recent stock trade was executed by Terri B Sebree on 12 September 2023, trading 12,401 units of ZYNE stock currently worth $16,493.
What does Zynerba Pharmaceuticals Inc do?
at zynerba pharmaceuticals (nasdaq: zyne), we are dedicated to developing next-generation synthetic cannabinoid therapeutics for transdermal delivery for patients with significant unmet medical needs. our mission is to improve the lives of patients battling severe health conditions including refractory epilepsy, osteoarthritis, fragile x syndrome, fibromyalgia and peripheral neuropathic pain through these therapeutics. our development pipeline includes patent-protected synthetic transdermal cannabinoid products, cbd gel – zyn002 and thc pro-drug patch – zyn001, which we believe will provide new treatment options for patients as well as additional treatment options for patients not currently receiving adequate relief or otherwise experiencing intolerable side effects from current treatment regimes.
What does Zynerba Pharmaceuticals Inc's logo look like?
Complete history of Mr. Anido stock trades at Scynexis Inc a Zynerba Pharmaceuticals Inc
Zynerba Pharmaceuticals Inc executives and stock owners
Zynerba Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Armando Anido,
Chairman of the Board, Chief Executive Officer -
Terri Sebree,
President -
Armando Anido MBA,
Chairman & CEO -
James Fickenscher,
Chief Financial Officer, Vice President - Corporate Development -
Terri B. Sebree,
Pres -
James E. Fickenscher,
CFO, VP of Corp. Devel. & Treasurer -
Suzanne Hanlon,
Vice President, General Counsel, Secretary -
William Roberts,
Vice President, Investor Relations and Corporate Communications -
Pamela Stephenson,
Independent Director -
Kenneth Moch,
Independent Director -
Daniel Kisner,
Independent Director -
William Federici,
Independent Director -
John Butler,
Independent Director -
Warren Cooper,
Lead Independent Director -
Brian Rosenberger,
Vice President - Commercial and Business Development -
Joseph Apostolico,
VP of HR -
Suzanne M. Hanlon,
Sec., VP & Gen. Counsel -
Dr. Joseph Palumbo,
Chief Medical Officer -
Thomas L Harrison,
Director -
Michael Rapp,
10% owner -
Cynthia Ann Rask,
Director -
Albert P Parker,
Chief Legal Officer -
Richard A Baron,
Chief Financial Officer -
Kenneth T Jones,
See Remarks